Association between prognosis and SEMA4D/Plexin-B1 expression in various malignancies
A meta-analysis

Yibo Yang, MD, PhD; Jing Wang, MD; Hui Li, MD, PhD; Lihong Liu, MD, PhD; Maojin Yao, PhD; Tao Xiao, MD, PhD

Abstract

Introduction: SEMA4D and its high affinity receptor Plexin-B1 showed a promising prognosis prediction for carcinoma patients in recent studies. We performed a meta-analysis to evaluate the prognostic role of them in various malignancies.

Methods: A systematic literature search was performed in PubMed, Embase, Web of Science, and CNKI from inception till July 2017. Eligible studies were identified by different reviewers. Hazard ratios (HRs)/related ratios (RRs) and their corresponding 95% confidence intervals (CIs) were extracted to investigate the relevance between malignancies prognosis and SEMA4D/Plexin-B1.

Results: Around 2638 patients from 14 studies were included in this meta-analysis. High expression of SEMA4D was significantly associated with overall survival (OS) and disease-free survival/progression-free survival/recurrence-free survival (DFS/PFS/RFS) in tumors (respectively, HRos=2.05, 95%CI: 1.68–2.50, P < .001; HRdfs=pfs=rfs=1.59, 95%CI: 1.27–1.98, P < .001). However, the relationship between SEMA4D expression and prognosis of breast cancer patients was failed to find (HR=0.76, 95%CI=0.32–1.82, P = .539). Plexin-B1 level showed a significant positive correlation both with OS and DFS of Caucasian breast cancer patients (respectively, HRos=0.56, 95%CI: 0.39–0.79, P = .001; HRdfs=0.68, 95%CI=0.51–0.90, P = .008)

Conclusions: SEMA4D could be a prospective biomarker for prognostic prediction of various malignancies except breast cancer. For Caucasian breast cancer patients, SEMA4D’s high affinity receptor Plexin-B1 showed a significant positive correlation with survival.

Abbreviations: APCs = antigen-presenting cells; BC = breast cancer; CIs = confidence intervals; CNS = central nervous system; CRC = colorectal cancer; DFS = disease-free survival; EOC = epithelial ovarian cancer; HNSCC = head and neck squamous cell carcinoma; HRs = hazard ratios; IHC = immunohistochemistry; KM = Kaplan-Meier curves; NOS = Newcastle-Ottawa scale; OS = overall survival; PFS = progression-free survival; qPCR = quantitative polymerase chain reaction; RFS = recurrence-free survival; RRs = related ratios; STS = soft tissue sarcoma.

Keywords: malignancy, meta-analysis, Plexin-B1, prognosis, SEMA4D

1. Introduction

Cancer, one of the greatest worldwide public health issues, remains the leading cause of death in some developing countries.[11–13] Even though a long-term survival rate of breast and colorectal cancer has been increased significantly in most developed countries, other types of cancers and sarcomas are still fatal such as liver and lung cancer.[14] Searching tumor biomarkers for diagnosis, treatment, and prognosis is the breaking point of clinical cancer research, such as alpha fetal protein in liver cancer and prostate-specific antigen in prostate cancer.[5]

Semaphorin4D (SEMA4D), also known as CD100, is a 150 kD glycoprotein classified as a member of class IV semaphorin family.[6] SEMA4D functions as both a ligand, binding to Plexin-B1 or CD72, and as a receptor.[8] SEMA4D was first found in immune cells, especially highly expressed in resting T cells,[6] and upregulated in B cells, APCs (antigen-presenting cells) when these cells were activated.[9] Initial study suggested that SEMA4D was involved in activation of T cells.[6] SEMA4D enhanced the antibody synthesis of B cells and matured APCs by competitively inhibiting CD72/SHIP-1 negative regulation.[9] SEMA4D was observed in embryonic and postnatal CNS (central nervous system), nonspecifically but highly expressing in oligodendrocytes[10] and had been proved as an axonal guidance factor via its high affinity receptor Plexin-B1.[11]

Increasing studies of SEMA4D have focused on oncological aspect.[12–14] SEMA4D has a relatively high expression in a series of solid tumor cells comparing with normal tissue cells, such as HNSCC (head and neck squamous cell carcinoma), breast cancer,[16] prostate cancer,[17] CRC (colorectal cancer),[18,19] STS (soft tissue sarcoma),[13,20] EOC (epithelial ovarian cancer),[21] pancreatic cancer,[22] and cervical cancer.[23] Cumulated
evide

cence reveals that SEMA4D participates in tumor angiogene-
sis,[12,24] regulation of tumor microenvironment[14] and cancer progression.[25] Plexin-B1 that has a high expression on VECs
(vascular endothelial cells) surface can activate VECs proangi-
genic property after combining with its high affinity ligand
SEMA4D.[15] The mechanism how SEMA4D/Plexin-B1 complex
promotes angiogenesis is inconclusive, but one thing is con-
firmed that SEMA4D is an independent angiogenic factor out of other
classic molecules such as VEGF-a, bFGF and HGF.[21] SEMA4D also
affects tumor microenvironment by negative regulating differenti-
ation of monocyte[26] and TAMs (tumor-associated macrophages)
have been proved as a main source of
SEMA4D.[14] Moreover, high expressing level of SEMA4D has
been proved to predict a worse survival in some carcin-
omas,[13,17–23] while other study showed a diverse opinion.[16,27]
There was no unified conclusion whether SEMA4D can be a
promising cancer prognostic biomarker.

Plexin-B1 is a transmembrane receptor which acts through its
high affinity ligand SEMA4D, has a series of functions such as
regulation of immune cells, axon guidance, tumor angiogenesis,
and invasion.[27] Plexin-B1 has an overexpression in colorectal,
hepatocellular, breast, pancreatic carcinoma tissue or cell lines.[19,22,24,26] Met or Ron from downstream of SEMA4D/
Plexin-B1 is critical for tumor invasive function.[12] Plexin-B1 is
also thought to be a predict prognostic marker for several types
of tumor, breast cancer in particular.[16,29–31] This meta-analysis
is performed to assess the prognostic value of SEMA4D and Plexin-
B1 expression in various malignancies.

2. Methods

Ethics committee is inapplicable in this meta-analysis.

The present review was conducted according to the guidelines
of Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA)[32] and Meta-Analysis of Observational
Studies in Epidemiology group (MOOSE).[33]

2.1. Search strategy

Literature search was performed in online PubMed (http://www.
cbi.nlm.nih.gov/pubmed), Embase (http://www.embase.com/
home), Web of Science (http://wokinfo.com/) and CNKI
(http://www.cnki.net/) up to July 1, 2017. Two sets of search
terms were adopted for simultaneously retrieval, namely:
“CD100 or semaphorin 4D or SEMA4D or Plexin-B1 or
semaphorin receptor protein” and “cancer or carcinoma or
malignant neoplasm or tumor or benign neoplasm.” No language
or other restriction were made. After screening the titles, authors
and years, the duplications were removed directly. References
from searched publications were manually reviewed for missing
relevant literatures. All literatures search was separately
performed by 2 reviewers (YYB and LH).

2.2. Inclusion and exclusion criteria

The studies were defined eligible in this meta-analysis by
following criteria: the patients had been diagnosed any type of
cancer or sarcoma, SEMA4D or Plexin-B1 expression was
measured from tumor tissues or body fluids, the correlation
between SEMA4D or Plexin-B1 expression and patients clinical
survival was available, such as either the hazard ratio (HR) or the
relative ratio (RR) with corresponding 95% confidence intervals
(CIs) or sufficient data which could be used to calculate HRs/RRs
and corresponding 95% CIs.

Articles with the following criteria were excluded: case reports,
letters, reviews, conference abstracts, and animal or laboratory
studies, nondichotomous studies, studies that used the same or
overlapped population, studies which were lacked of key data
regarding prognosis, study with fewer than 15 patients. Eligible
studies were independently and carefully identified from all
literatures in triplicate by 2 reviewers (YYB and LH) after
discussion.

2.3. Data extraction

To rule out any discrepancy, 2 investigators (YYB and LLH)
independently evaluated and extracted relevant information
according to the guideline of a critical review checklist. The
following characteristics were collected from each eligible article,
including title, first author’s name, year of publication, name of
journal, pathological diagnosis of cancer, sample source, origin
of population, number of cases, detection method, TNM stage,
cut-off value, follow-up, and survival analysis endpoint with
respect to corresponding HR/RR and 95% CIs.

The relative ratio (RR) which determined from Cox’s multiple
regression model was acceptable in this study.[34] HRs/RRs with
their 95% CIs were extracted by using the following 2 methods.
The univariate analysis results for survival which were reported
in eligible studies were considered as the aggregation of the
survival data. In most instances, the reported HRs/RRs with
corresponding 95% CIs and P values were directly derived from
the original publications or the E-mails from the authors, with an
HR/RR of >1 being associated with elevated risk of mortality or
recurrence. Reported HRs/RRs are the most accurate methods. In
the absence of HRs/RRs and 95% CIs, the data which were
extracted from Kaplan–Meier curves were used to estimate the
HRs following the method applied in previous meta-analysis.[35]
All the HRs/RRs extraction were performed by all the authors
with consensus.

2.4. Quality assessment

The quality of eligible study was systematically evaluated
according to a critical review checklist of the Dutch Cochrane
Centre proposed by MOOSE specifically for prognosis meta-
analyses.[33]

The Newcastle–Ottawa scale (NOS) for quality of cohort
studies was adopted as quality assessment criteria.[36] The
evaluated items were classified into 3 aspects including selection
of cohorts (4 scores), comparability of cohorts (2 scores) and
assessment of outcome (3 scores) with a maximum of 9 scores.
High scores evaluation outcome revealed the preciseness of study.
The assessments were performed independently by 2 reviewers
(YYB and WJ) and aggregated with consensus.

2.5. Statistical analysis

All analyses were conducted by mainly using STATA package
version 12.0 (STATA Corporation, College Station, TX), and Z-
test was computed by RevMan version 5.3.5 (Cochrane
Collaboration, Oxford, UK).

Pooled HRs with 95% CIs were calculated to evaluated the
effect of SEMA4D and Plexin-B1 expression on the survival
of cancer. Patients with overexpression of target gene were indicated
a poor prognosis if HR > 1 without its 95% CI overlapped with
1. Z-test was utilized to evaluate the significance of merged HRs.
Heterogeneity of pooled HRs was carried out by using Higgins
I-square ($I^2$) and Cochran’s Q-test statistic. The fixed-effects model (Mantel–Haenszel test) was applied on no significant heterogeneity outcome ($P_{\text{heterogeneity}}>0.05$ or $I^2<50\%$). Otherwise, a random-effects model (Der Simonian and Laird method) was used. Subgroup analysis and meta-regression was further performed to explain the source of heterogeneity.\[37\]

One-way sensitivity analyses were processed by omitting 1 study at a time to assess the consistency of the combined results. The potential publication bias were assessed by using Begg’s funnel plot\[39\] and Egger’s bias.\[40\] The trim and fill method would be performed if a publication bias existed. All statistical tests were 2-sided, and $P<.05$ was regarded as statistically significant.

3. Result

3.1. Eligible studies and characteristics

As showed in the flow diagram of literatures screening (Fig. 1), a total of 373 articles were originally searched from PubMed, Embase, Web of Science, and CNKI. Full text screening was performed based on the inclusion and exclusion criteria, and 18 candidate studies were eligible. When data extraction due to using overlapping cohort 4 literatures was further excluded. Finally, 14 articles were qualified for our meta-analysis,\[13,16–23,29–31,41,42\] 11 for SEMA4D\[13,16–23,41,42\] and 4\[16,29–31\] for its receptor Plexin-B1. Of the SEMA4D related studies, 9 for overall survival (OS), 6 for disease-free survival (DFS)/progression-free survival (PFS)/recurrence-free survival (RFS). Of the Plexin-B1 related studies, 3 for OS and 2 for DFS.

The requisite data was extracted from 14 eligible studies and integrated into Table 1. A total of 1375 patients from United States, China, Brazil, Japan, and Pakistan were included in SEMA4D group while 1410 patients from Pakistan, Germany and Netherlands were included in Plexin-B1 group. Interestingly, all 4 articles of Plexin-B1 group focused on breast cancer research, and SEMA4D group showed a wide variety of malignant tumors including prostate cancer, colorectal cancer (CRC), soft tissue sarcoma (STS), epithelial ovarian cancer (EOC), breast cancer, cervical cancer, and pancreatic cancer. The commonest method to detect SEMA4D expression in selected studies was immunohistochemistry (IHC) staining, while the...
majority of studies evaluated Plexin-B1 expression by microarray. Staining assessment score was used to set up the dichotomous cut-off value in all IHC studies. The rest of literatures mostly used Median as cut-off value. There were 13 studies used tumor tissue as sample, within them there was one study took ascites as comparison to tissue, besides one study used blood.

The Newcastle-Ottawa scale (NOS) was used to assess the methodological quality of eligible literatures. All papers’ NOS ranged from 5 to 9 (Table 2), with an average of 7.12. Study with scores ≥7 was defined a high-quality record, otherwise low.

3.2. Evidence synthesis

All pooled HRs and heterogeneity results are shown in Table 3 (Supplemental figure 1–5, http://links.lww.com/MD/C809) which is divided into SEMA4D sublist and Plexin-B1 sublist. A fixed effect model was applied to pool HRs/RRs from 9 SEMA4D OS studies included 1078 patients. The combined HR is 2.03 with corresponding 95%CI 1.68–2.50, which revealed that overexpression of SEMA4D may predict a poor prognosis of multiple malignancies (Fig. 2A). Subgroup analyses of overall survival were categorized by ethnicity of patients, diagnosis of diseases, assay method, sample, source of HRs/RRs and quality assessed classification. There were significant associations between high level expression of SEMA4D and poor survival in Asian patients (HR = 2.05, 95%CI: 1.65–2.54, P < .001), in patients with colorectal cancer (HR = 2.16, 95%CI: 1.44–3.25, P < .001) and epithelial ovarian cancer (HR = 2.92, 95%CI: 1.80–4.73, P < .001), in studies which examined SEMA4D with immunohistochemistry staining (HR = 2.05, 95%CI: 1.65–2.54, P < .001), in tissue samples (HR = 2.01, 95%CI: 1.62–2.49, P < .001), in studies which reported HRs/RRs (HR = 2.23, 95%CI: 1.81–2.75, P < .001) and in high methodological quality studies (HR = 2.07, 95%CI: 1.63–2.62, P < .001) (Supplemental figures 1–5, http://links.lww.com/MD/C809).

Similar to total OS analysis result, the high expression of SEMA4D was significantly associated with a poor DFS/PFS/RFS in Asian patients (HR = 2.05, 95%CI: 1.68–2.30, P < .001) (Supplemental figure 2B). Subgroup analyses of DFS/PFS/RFS were performed in the same categories. Correlations between SEMA4D level and DFS/PFS/RFS were observed in Asian group (HR = 1.86, 95%CI: 1.59–2.18, P < .001) (Fig. 2B).

### Table 1
The requisite characteristic of all 14 eligible studies.

| Author and Year | Ethnicity | Number | Diagnosis | TNM stage | Sample | Assay method | Cut-off | Follow-up | Endpoint | HR/RR |
|-----------------|-----------|--------|-----------|-----------|--------|--------------|---------|-----------|----------|-------|
| Ross et al 2012[17] | Caucasian | 138 | Prostate Cancer | NG | Blood | qPCR | 21.21 | 30 | OS | R |
| Mu et al 2014[16] | Asian | 86 | Colorectal Cancer | I–IV | Tissue | IHC | –/+ | 36.55 | OS | KM |
| Campos et al 2013[20] | Caucasian | 65 | Soft Tissue Sarcoma | I–III | Tissue | IHC | –/+ | 45 | DFS | R |
| Chen et al 2013[41] | Asian | 67 | Epithelial Ovarian Cancer | I–IV | Tissue | IHC | –/+ | 41 | OS | DFS |
| Chen et al 2012[21] | Asian | 124 | Epithelial Ovarian Cancer | I–IV | Tissue | IHC | –/+ | 41 | OS | DFS |
| Chi et al 2009[18] | Asian | 81 | Soft Tissue Sarcoma | NG | Tissue | IHC | 1/2/3 | 60 | OS | DFS |
| Mailk et al 2013[16] | Caucasian | 147 | Breast Cancer | I–IV | Tissue | qPCR | 24.82 | 120 | OS | KM |
| Liu et al 2014[23] | Asian | 232 | Cervical Cancer | I–III | Tissue | IHC | 1/2/3 | 18.3 | OS | KM |
| Kato et al 2011[22] | Asian | 99 | Pancreatic Cancer | I–IV | Tissue | IHC | 1/2/3 | 72 | OS | KM |
| Ikeya et al 2016[19] | Asian | 226 | Colorectal Cancer | I–IV | Tissue | IHC | 1/2/3 | 8 | OS | DFS |
| Xu et al 2012[22] | Asian | 110 | Breast Cancer | I–IV | Tissue | IHC | 1/2/3 | 72 | OS | KM |
| Worzfeld et al 2012[20] | Caucasian | 200 | Breast Cancer | NG | Tissue | Microarrays | Median | 8 | DFS | KM |
| Rody et al 2009[30] | Asian | 67 | Epithelial Ovarian Cancer | I–IV | Tissue | IHC | 1,2/3 | 67 | DFS | KM |
| Xu et al 2014[18] | Asian | 86 | Colorectal Cancer | I–IV | Blood | qPCR | 21.21 | 30 | OS | KM |
| Xu et al 2012[22] | Caucasian | 138 | Prostate Cancer | NG | Blood | qPCR | 21.21 | 30 | OS | KM |

### Table 2
The Newcastle–Ottawa scale for methodological quality of eligible literatures.

| Studies | Representativeness of the exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Outcome was not present at start of study | Based on the design or analysis | Assessment of outcome | Follow-up long enough for outcomes to occur | Adequacy of follow-up of cohorts | Total score |
|---------|-------------------------------------|-----------------------------------|--------------------------|------------------------------------------|--------------------------------|-----------------------|---------------------------------------------|-----------------------------|-----------|
| Ross et al 2012[17] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Mu et al 2014[16] | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 6 | |
| Campos et al 2013[20] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Chen et al 2013[41] | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 8 |
| Chen et al 2012[21] | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 8 |
| Chi et al 2009[18] | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 8 |
| Mailk et al 2013[16] | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 7 | |
| Liu et al 2014[23] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 | |
| Kato et al 2011[22] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 6 | |
| Ikeya et al 2016[19] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 5 | |
| Xu et al 2012[22] | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 7 | |
| Rody et al 2009[30] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 | |
| Vljer et al 2002[21] | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 | |
1.25–1.95,  

1.51,  

95%CI: 1.10–2.09,  

P = .012) and epithelial ovarian cancer group (HR = 1.97,  

95%CI: 1.30–2.98,  

P = .001), in both high and low methodological quality groups (respectively, HR_{Hi} = 1.59,  

95%CI: 1.37–1.93,  

P < .001;  

HR_{Lo} = 1.76,  

95%CI: 1.12–2.22,  

P < .001). Because all 6 studies assessed SEMA4D expression from tumor tissue by immunohistochemistry staining and reported the HRs/RRs, IHC group, tissue group and reported HRs/RRs group had a same result as the total DFS/PFS/RFS analysis (HR = 1.59,  

95%CI: 1.27–1.98,  

P < .001) (Supplemental figures 6–8, http://links.lww.com/MD/C809).

As noted, all 4 articles of Plexin-B1 group focused on Caucasian breast cancer research, so we only evaluated the relationship between Plexin-B1 level and Caucasian breast cancer patients’ survival. It turned out that elevated Plexin-B1 showed a significant association with favorable OS (HR = 0.56,  

95%CI: 0.39–0.79,  

P = .001) and DFS (HR = 0.68,  

95%CI: 0.51–0.90,  

P = .008) (Fig. 2C).

### 3.3. Heterogeneity analysis

All nonsubgroup pooled HRs were calculated in fixed effect model because of their low or no heterogeneity. Precisely, heterogeneity was found among the SEMA4D OS studies (P_{heterogeneity} = 0.185,  

I^{2} = 29.2%). To investigate the source of heterogeneity in SEMA4D OS group, a meta-regression was utilized to assess by year of publication, quality classification, sample, ethnicity, assay method and diagnosis, such as breast cancer, colorectal cancer and epithelial ovarian cancer. All main results were shown in Table 4. Breast cancer category (P = 0.057) dominantly induced heterogeneity rather than others categories.

### 3.4. Publication bias and sensitivity analysis

Publication bias was evaluated by Begg’s funnel plot and Egger’s test in OS group with 9 literatures and DFS/PFS/RFS group with 6 studies for SEMA4D. The Egger’s test outcome (Table 5, P > .05) and symmetrical Begg’s funnel plots (Fig. 3) showed no potential publication bias.

Sensitivity analyses of SEMA4D OS group and DFS/PFS/RFS group showed no significant variation on original result by omitting individual study (Fig. 4).

### Table 3

All pooled HRs and heterogeneity results.

| Variables     | Heterogeneity | Hypothesis | Model | Z     | P       | Studies | Patients |
|---------------|---------------|------------|-------|-------|---------|---------|----------|
|               | F             | P          |       |       |         |         |          |
| Sema4d        |               |            |       |       |         |         |          |
| OS            | 2.05 (1.68–2.50) | 29.20%     | .185  | Fixed | 7.16    | <.001   | 9        | 1078     |
| Ethnicity     |               |            |       |       |         |         |          |
| Asian         | 2.05 (1.65–2.54) | 31.80%     | .185  | Fixed | 6.50    | <.001   | 7        | 793      |
| Caucasian     | 1.45 (0.40–5.24) | 60.10%     | .113  | Random| 0.56    | .575    | 2        | 285      |
| Diagnosis     |               |            |       |       |         |         |          |
| CRC           | 2.16 (1.44–3.25) | 40.70%     | .194  | Fixed | 3.72    | <.001   | 2        | 312      |
| EOC           | 2.92 (1.80–4.73) | 31.70%     | .327  | Fixed | 4.35    | <.001   | 2        | 312      |
| BC            | 0.76 (0.32–1.82) | 0%         | .688  | Fixed | 0.61    | .539    | 2        | 257      |
| Method        |               |            |       |       |         |         |          |
| qPCR          | 1.45 (0.40–5.24) | 60.10%     | .113  | Random| 0.56    | .575    | 2        | 285      |
| IHC           | 2.05 (1.65–2.54) | 31.80%     | .185  | Fixed | 6.50    | <.001   | 7        | 793      |
| Sample        |               |            |       |       |         |         |          |
| Tissue        |               |            |       |       |         |         |          |
| Estimated     |               |            |       |       |         |         |          |
| Reported      | 2.23 (1.81–2.75) | 0%         | .459  | Fixed | 7.52    | <.001   | 6        | 735      |
| KM            | 1.09 (0.61–1.92) | 0%         | .529  | Fixed | 0.28    | .778    | 3        | 343      |
| NOS <7        | 1.76 (0.97–3.20) | 57.10%     | .054  | Random| 1.87    | .061    | 5        | 636      |
| >7            | 2.07 (1.63–2.62) | 0%         | .577  | Fixed | 5.93    | <.001   | 4        | 442      |
| Sema4d        |               |            |       |       |         |         |          |
| DFS/PFS/RFS   |               |            |       |       |         |         |          |
| Ethnicity     |               |            |       |       |         |         |          |
| Asian         | 1.56 (1.25–1.95) | 10.6%      | .346  | Fixed | 3.88    | <.001   | 5        | 730      |
| Diagnosis     |               |            |       |       |         |         |          |
| STS           | 1.51 (1.10–2.09) | 0%         | .351  | Fixed | 2.52    | .012    | 2        | 146      |
| EOC           | 1.97 (1.30–2.98) | 0%         | .993  | Fixed | 3.18    | .001    | 2        | 191      |
| NOS <7        | 1.58 (1.12–2.22) | 47.4%      | .149  | Fixed | 2.63    | .009    | 3        | 525      |
| >7            | 1.59 (1.37–1.93) | 0%         | .504  | Fixed | 3.14    | .002    | 3        | 270      |
| Plexin-B1     |               |            |       |       |         |         |          |
| OS            | 0.56 (0.39–0.79) | 0%         | .895  | Fixed | 3.24    | .001    | 3        | 462      |
| DFS           | 0.68 (0.51–0.90) | 0%         | .519  | Fixed | 2.64    | .008    | 2        | 968      |
4. Discussion

Neoplastic biomarkers are essential tools for cancer diagnosis, clinical therapy and survival. An ideal prognostic biomarker should match 2 features: accurate measurability and definite association with either pathologic progression or prognosis.\cite{43} SEMA4D are widely utilized in clinical pathology examination to auxiliary diagnose neurogenic tumor.\cite{44} Substantial evidence demonstrated that SEMA4D was involved in angiogenesis,

![Figure 2](image.png)

Table 4

| Study ID     | HR (95% CI) | % Weight |
|--------------|-------------|----------|
| RW Ross (2012) | 2.30 (1.39, 3.70) | 16.11    |
| L Mu (2014)   | 1.42 (0.67, 3.02) | 6.75     |
| Y Chen (2013) | 4.39 (1.70, 11.35) | 4.29     |
| Y Chen (2012) | 2.53 (1.45, 4.44) | 12.27    |
| ES Ch’ng (2007) | 1.66 (1.11, 2.44) | 24.89    |
| MF Malik (2015) | 0.57 (0.11, 3.02) | 1.41     |
| S Kato (2011) | 2.25 (1.33, 3.80) | 14.01    |
| T Ike (2016)  | 2.57 (1.59, 4.16) | 16.65    |
| XW Xu (2012)  | 0.85 (0.30, 2.36) | 3.63     |
| Overall (I² = 29.2%, p = 0.185) | 2.05 (1.68, 2.50) | 100.00   |

| Study ID     | HR (95% CI) | % Weight |
|--------------|-------------|----------|
| M Campos (2013) | 2.65 (0.78, 8.93) | 3.27     |
| Y Chen (2012)   | 1.97 (1.16, 4.37) | 11.14    |
| ES Ch’ng (2007) | 1.45 (1.02, 1.99) | 43.58    |
| HD Liu (2014)   | 2.46 (1.08, 5.64) | 7.10     |
| T Ike (2016)    | 1.08 (1.01, 2.87) | 17.97    |
| Y Chen (2013)   | 1.96 (1.15, 3.36) | 16.93    |
| Overall (I² = 33.3%, p = 0.395) | 1.59 (1.27, 1.98) | 100.00   |

| Study ID     | HR (95% CI) | % Weight |
|--------------|-------------|----------|
| OS           |             |          |
| MF Malik (2015) | 0.52 (0.33, 0.83) | 56.39    |
| V Vijver (2002) | 0.62 (0.36, 1.06) | 41.99    |
| Worzfeld (2012) | 0.61 (0.04, 9.73) | 1.63     |
| Subtotal (I² = 0.0%, p = 0.895) | 0.56 (0.03, 0.79) | 100.00   |
| DFS          |             |          |
| Worzfeld (2012) | 1.01 (0.29, 3.49) | 5.38     |
| A Rody (2009)  | 0.66 (0.49, 0.89) | 94.62    |
| Subtotal (I² = 0.0%, p = 0.519) | 0.68 (0.51, 0.90) | 100.00   |

95% CI = 95% confidence interval, BC = breast cancer, Coef. = coefficient, CRC = colorectal cancer, EOC = epithelial ovarian cancer, NOS = Newcastle-Ottawa scale, Std. err. = standard error.
regulation of tumor microenvironment and cancer progression of various types of tumors. Moreover, an anti-SEMA4D monoclonal antibody named VX15/2503 has been proved its broad-spectrum anti-tumor property in mouse and is entering clinical trials.\textsuperscript{[45]} However, no evidence proves novel insight that SEMA4D can be utilized as a prognostic biomarker in diverse malignant tumors.

In our cognizance, the present analysis is the first study to identify the prognosis predictive potency of SEMA4D in various types of malignancies. By collecting and combining survival

|                | Begg’s test | Egger’s test |
|----------------|-------------|--------------|
|                | z   | P | t   | P | 95%CI         |
| OS             | 0.73 | .466 | -0.92 | .388 | (-3.742, 1.645) |
| DFS/PFS/RFS    | 1.13 | .260 | 1.66  | .172 | (-1.082, 4.296) |

95%CI = 95% confidence interval, DFS = disease-free survival, OS = overall survival, PFS = progression-free survival, RFS = recurrence-free survival.

Table 5
Begg’s test and Egger’s test for publication bias analysis on SEMA4D studies.

Figure 3. (A) Begg’s funnel plot for publication bias of 9 studies in Sema4D OS group. (B) Begg’s funnel plot for publication bias of 6 studies in Sema4D DFS/PFS/RFS group.
indexes from all eligible literatures, we concluded that rising expression of SEMA4D was significantly associated with OS and DFS/PFS/RFS in tumors (respectively, HR_{OS}=2.05, 95%CI: 1.68–2.50, \(P<.001\); HR_{DFS/PFS/RFS}=1.59, 95%CI: 1.27–1.98, \(P<.001\)). Heterogeneity which existed in overall survival analyses (\(I^2=29.3\%, \, P=.183\)) was mainly attributed to the outcome of breast cancer patients. Besides, the relationship between SEMA4D expression and prognosis of breast cancer patients was failed to find (HR=0.76, 95%CI: 0.32–1.82, \(P=.539\)). These statistical negative results revealed that SEMA4D probably was not an accurate prognosis predictor in breast cancer. The pooled survival results of Plexin-B1, SEMA4D high affinity receptor, precisely remedied the insufficient in breast cancer studies: Plexin-B1 level showed a significant positive correlation both with OS and DFS (respectively, HR_{OS}=0.56, 95%CI: 0.39–0.79, \(P=.001\); HR_{DFS}=0.68, 95%CI: 0.51–0.90, \(P=.008\)).

SEMA4D is over-expressed in various tumor tissues.\(^{[46]}\) Abundant vivo evidence revealed SEMA4D effected tumor progress by regulating tumor angiogenesis and tumor environment.\(^{[14,41]}\) Most of selected studies support a consensus that SEMA4D acts as an angiogenic promoter mainly through Plexin-B1 rather than VEGF-a.\(^{[13,16–23]}\) Base on the over-expression of Plexin-B1 in endothelial cells, SEMA4D/Plexin-B1 signal efficiently enhances endothelium migration.\(^{[24]}\) The mechanism of SEMA4D tubulogenesis is mainly because of the activation of tyrosine kinase Met and Rho pathways.\(^{[12,24]}\) Interestingly, grafting SEMA4D over-expressing melanoma to Plexin-B1 deficient mouse shows no significant reduction of neovascularization.\(^{[28]}\) It is probably because that Plexin-B1 is not the
essential for SEMA4D promoting tumor angiogenesis, or maybe because SEMA4D/Plexin-B1 interaction only functions at the early stage of tumor formation.

Moreover, SEMA4D regulates tumor environment by inhibiting monocyte migration and prompting monocyte differentiation to M2 macrophages which acts as a tumor-promotor.[13] Chen’s study[14] showed a strong association between SEMA4D expression and M2 macrophages count both in epithelial ovarian cancer (EOC) tumor sample and in malignant ascites.

SEMA4D does not seem to be an accurate prognosis predictor for breast cancer base on the result of our study (HR = 0.76, 95% CI = 0.32–1.82, P = .539). Fortunately, there were several literatures[29–31,42] which demonstrated the inverse correlation between Plexin-B1 and prognosis of patients. Swiercz’s study[43] indicated Plexin-B1 stimulated tumor cell migration via tyrosine kinase receptor ErbB-2 pathway while antimigrated via met pathway. He believed that the effect of SEMA4D/Plexin-B1 mainly depended on the superior pathway. Based on our result, regardless of ErbB-2 or Met took charge, Plexin-B1 was an independent prognosis marker for breast cancer patients.

Nevertheless, there are several limitations of the present analysis. First, the number of the cancer types which included in this meta-analysis were inadequate. There were 7 kinds of cancer in 14 studies, including 1520 breast cancer patients and only 99 pancreatic cancer patients. The small sample size can unavoidably cause sample bias and random errors. Thus, more studies with larger population are necessary for further analysis. Second, several HRs were calculated based on Kaplan–Meier curves; some minor errors were generated during calculation. Third, the cut-off value of SEMA4D and Plexin-B1 expression were various. Besides, IHC staining assessment which were used to set up the dichotomous cut-off value was lack of unified and objective criterion for staining evaluation.[44] Fourth, all Plexin-B1 group articles were breast cancer researches and all these researches were focus on Caucasian. As we all known, Caucasian has significantly higher incidence and mortality rates of breast cancer than Asian and African,[45] and there was no evidence proved that Plexin-B1 expression had a relationship with the survival of Asian and African breast cancer patients. Finally, all eligible studies in our meta-analysis were published in English and Chinese, in spite of no language restriction in Search Strategy that will cause language bias.

5. Conclusion
In summary, the present analysis demonstrated that SEMA4D could be a prospective biomarker for prognostic prediction of various malignancies except breast cancer. For Caucasian breast cancer patients, SEMA4D’s high affinity receptor Plexin-B1 showed a significant positive correlation with survival. However, the eligible studies are insufficient, more comprehensive studies are needed to support this conclusion.

Author contributions
Conceptualization: Yibo Yang. Data curation: Yibo Yang, Hui Li. Formal analysis: Yibo Yang. Funding acquisition: Hui Li, Tao Xiao. Methodology: Yibo Yang, Hui Li. Project administration: Yibo Yang, Jing Wang, Lihong Liu. Resources: Yibo Yang. Software: Yibo Yang.

Supervision: Maojin Yao. Validation: Yibo Yang. Writing – original draft: Yibo Yang. Writing – review & editing: Yibo Yang, Jing Wang, Maojin Yao, Tao Xiao.

References
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. Epub ahead of print.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.
[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
[4] Liu L, Global sex differences in cancer mortality with age and country specific characteristics. Asian Pac J Cancer Prev 2016;17:3469–76.
[5] Song P, Tang Q, Feng X, et al. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. Scand J Clin Lab Invest Suppl 2016;245:570–76.
[6] Bougeret C, Mansur IG, Dastot H, et al. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J Immunol 1992;148:318–23.
[7] Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999;99:71–80.
[8] Herold C, Bismuth G, Benussan A, et al. Activation signals are delivered through two distinct epitopes of CD100, a unique 150 kDa human lymphocyte surface structure previously defined by BB18 mAb. Int Immunol 1995;7:1–8.
[9] Hall KT, Bousoull L, Schultz JI, et al. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci U S A 1996;93:1750–5.
[10] Moreau-Fauvarque C, Kumanogoh A, Camand E, et al. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J Neurosci 2003;23:9229–39.
[11] Masuda K, Furuyama T, Takahara M, et al. Sema4D stimulates axonal outgrowth of embryonic DRG sensory neurons. Genes Cells 2004;9:821–9.
[12] Consotto P, Valdemibri D, Corso S, et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005;105:4321–9.
[13] Ch’ng E, Tomita Y, Zhang B, et al. Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer 2007;110:164–72.
[14] Sierra JR, Corso S, Caione L, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med 2008;205:1673–85.
[15] Takada H, Ibaragi S, Eguchi T, et al. Semaphorin4D and PlexinB1 predicts disease recurrence in colorectal cancer. Oncol Lett 2015;9:1509–13.
[16] Malik MF, Ye L, Jiang WG. Reduced expression of semaphorin4D and Plexin-B in breast cancer is associated with poorer prognosis and the potential linkage with oestrogen receptor. Oncol Rep 2015;34:1049–57.
[17] Ross RW, Galisky MD, Scher HI, et al. A whole-blood RNA transcription-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol 2012;13:1105–13.
[18] Wu L, Wang J, Guo X, et al. [Correlation and clinical significance of expressions of HIF-1alpha and Sema4D in colorectal carcinoma tissues]. Zhonghua Wei Chang Wai Ke Za Zhi 2014;17:388–92.
[19] Ikeya T, Maeda K, Nagahara H, et al. The combined expression of Semaphorin4D and PlexinB1 predicts disease recurrence in colorectal cancer. BMC Cancer 2016;16:525.
[20] Campos M, SG DFCI, Ribeiro GG, et al. Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively. Oncol Lett 2013;5:1527–33.
[21] Chen Y, Zhang L, Pan Y, et al. Over-expression of semaphorin4D, bypoxia-inducible factor-1alpha and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. Int J Mol Sci 2012;13:13264–74.
[22] Kato S, Kubota K, Shimamura T, et al. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci 2011;102:2029–37.
[23] Liu H, Yang Y, Xiao J, et al. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients. Microvasc Res 2014;93:1-8.
[24] Basile JR, Racar A, Zhu T, et al. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res 2004;64:5212–24.
[25] Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289–300.
[26] Delaire S, Billard C, Tordjman R, et al. Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. J Immunol 2001;166:4348–54.
[27] Rody A, Holtrich U, Gaetje R, et al. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 2007;13:1113–22.
[28] Fazzari P, Penachioni J, Gianola S, et al. Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis. BMC Dev Biol 2007;7:55.
[29] Worzfeld T, Swiercz JM, Looso M, et al. ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis. J Clin Invest 2012;122:1296–305.
[30] Rody A, Karn T, Ruckhaberle E, et al. Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers - results of a large scale microarray analysis. Eur J Cancer 2009;45:405–13.
[31] van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009.
[32] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
[33] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12.
[34] Ouyang Y, Li H, Bu J, et al. Hypoxia-inducible factor-1 expression predicts osteosarcoma patients’ survival: a meta-analysis. Int J Biol Markers 2016;31:e229–234.
[35] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
[36] Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–8.
[37] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.
[38] Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559–73.
[39] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
[40] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
[41] Chen Y, Zhang L, Lv R, et al. Overexpression of Semaphorin4D indicates poor prognosis and prompts monocyte differentiation toward M2 macrophages in epithelial ovarian cancer. Asian Pac J Cancer Prev 2013;14:5883–90.
[42] Xu X. The expressions of Sema4D and HER-2 proteins in breast cancers and their clinical significance. J Chin Phys 2012;14:1017–21.
[43] Tormey DC, Waalkes TP. Biological markers as prognostic and clinical evaluation tools. Eur J Cancer 1980;suppl 1:21–4.
[44] Rizzolio S, Tamagnone L. Semaphorin signals on the road to cancer invasion and metastasis. Cell Adh Migr 2007;1:62–8.
[45] Fisher TL, Seils J, Reilly C, et al. Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials. Cytometry B Clin Cytom 2016;90:199–208.
[46] Ch'ng ES, Kumanogoh A. Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer 2010;9:251.
[47] Swiercz JM, Worzfeld T, Offermanns S. ErbB-2 and met reciprocally regulate cellular signaling via plexin-B1. J Biol Chem 2008;283:1893–901.
[48] Varghese F, Bukhari AB, Malhotra R, et al. IHC Profi ler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One 2014;9:e96801.
[49] DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2013: Convergence of incidence rates between black and white women. CA Cancer J Clin 2016;66:31–42.